Werewolf Therapeutics (NASDAQ:HOWL) Downgraded to “Sell” Rating by Wall Street Zen

Wall Street Zen lowered shares of Werewolf Therapeutics (NASDAQ:HOWL) from a hold rating to a sell rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $3.75.

Werewolf Therapeutics Stock Up 9.7%

Shares of NASDAQ HOWL opened at $0.68 on Friday. The business’s 50 day moving average price is $0.81 and its 200 day moving average price is $0.85. The firm has a market cap of $33.05 million, a P/E ratio of -0.55 and a beta of 0.41. Werewolf Therapeutics has a 52 week low of $0.53 and a 52 week high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its earnings results on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. As a group, research analysts expect that Werewolf Therapeutics will post -1.29 earnings per share for the current year.

Insider Transactions at Werewolf Therapeutics

In other Werewolf Therapeutics news, Director Luke Evnin sold 168,262 shares of the business’s stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $0.72, for a total value of $121,148.64. Following the completion of the transaction, the director directly owned 1,785,687 shares of the company’s stock, valued at approximately $1,285,694.64. The trade was a 8.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 581,111 shares of company stock valued at $417,052 over the last three months. Insiders own 23.60% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Regal Investment Advisors LLC lifted its holdings in Werewolf Therapeutics by 93.3% in the fourth quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock valued at $33,000 after acquiring an additional 25,389 shares during the period. Vontobel Holding Ltd. lifted its holdings in Werewolf Therapeutics by 66.7% in the fourth quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock valued at $38,000 after acquiring an additional 24,003 shares during the period. Renaissance Technologies LLC lifted its holdings in Werewolf Therapeutics by 48.6% in the fourth quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock valued at $429,000 after acquiring an additional 221,766 shares during the period. Susquehanna International Group LLP lifted its holdings in Werewolf Therapeutics by 16.9% in the third quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock valued at $183,000 after acquiring an additional 13,439 shares during the period. Finally, Citadel Advisors LLC acquired a new position in Werewolf Therapeutics in the third quarter valued at approximately $304,000. 64.84% of the stock is owned by institutional investors and hedge funds.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.